PTAB invalidates Teva’s Copaxone patents

25-08-2016

PTAB invalidates Teva’s Copaxone patents

Lenka Horavova/shutterstock.com

The Patent Trial and Appeal Board (PTAB) has invalidated claims in two Teva-owned patents covering Copaxone (glatiramer acetate injection), prompting the Israel-based company to announce its intention to appeal against the ruling.


PTAB, Teva, Copaxone, patents, ANDA

LSIPR